NCT03122236

Brief Summary

Loss of mobility and cognitive ability are serious conditions that threaten the independence of older adults. The objective of this study is to initiate a line of research to develop a novel therapeutic intervention to enhance both mobility and cognition via neuroplasticity of frontal/executive circuits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 7, 2017

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 20, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2020

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 6, 2021

Completed
3.3 years until next milestone

Results Posted

Study results publicly available

June 14, 2024

Completed
Last Updated

June 14, 2024

Status Verified

June 1, 2024

Enrollment Period

3 years

First QC Date

April 7, 2017

Results QC Date

February 23, 2024

Last Update Submit

June 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mobility: Figure-of-eight Walking Test (Figure-8 Walk Test)

    Time to complete a walking course at usual pace. The course is 15 feet in length and arranged as a Figure-8 pattern.

    Change (value at 6 weeks minus value at baseline)

Secondary Outcomes (1)

  • Cognitive Composite Executive Score on EXAMINER Battery

    Change (value at 6 weeks minus value at baseline)

Study Arms (3)

Standard walking with Sham tDCS

ACTIVE COMPARATOR

Neurorehabilitation of Standard Walking and Sham Transcranial Direct Current Stimulation (Sham tDCS)

Behavioral: Neurorehabilitation of Standard WalkingDevice: Sham Transcranial Direct Current Stimulation (Sham tDCS)

Complex walking with Sham tDCS

ACTIVE COMPARATOR

Neurorehabilitation of Complex Walking and Sham Transcranial Direct Current Stimulation (Sham tDCS)

Behavioral: Neurorehabilitation of Complex WalkingDevice: Sham Transcranial Direct Current Stimulation (Sham tDCS)

Complex walking with Active tDCS

ACTIVE COMPARATOR

Neurorehabilitation of Complex Walking and Active Transcranial Direct Current Stimulation (Active tDCS)

Behavioral: Neurorehabilitation of Complex WalkingDevice: Active Transcranial Direct Current Stimulation (Active tDCS)

Interventions

Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.

Standard walking with Sham tDCS

Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.

Complex walking with Active tDCSComplex walking with Sham tDCS

tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the "activity-dependent neuroplasticity" that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.

Also known as: Soterix Direct Current Stimulator
Complex walking with Sham tDCSStandard walking with Sham tDCS

tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the "activity-dependent neuroplasticity" that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.

Also known as: Soterix Direct Current Stimulator
Complex walking with Active tDCS

Eligibility Criteria

Age65 Years - 110 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • preferred 10m walking speed \< 1.0 m/s
  • th-80th percentile rank (age and education corrected score) on NIH toolbox executive assessments: Card Sort Test and Flanker test
  • willingness to be randomized to either intervention and to participate in all aspects of study assessment and intervention

You may not qualify if:

  • contraindications to non-invasive brain stimulation and/or MRI including metal in the head, pacemaker, known abnormal cranial fissures/holes.
  • difficulty communicating with study personnel
  • uncontrolled hypertension at rest (systolic \> 180 mmHg and/or diastolic \> 100 mmHg)
  • low vision that cannot be corrected by wearing glasses. Low visual will be operationally defined as visual acuity less than 20/70 on a standard eye chart, or difficulty performing complex walking tasks due to visual conditions affecting accurate navigation around and over obstacles (self-reported or observed by examiner).
  • illiterate, due to the likelihood of difficulties performing some of the cognitive tasks
  • non-English speaking, due to the likelihood of difficulties following instructions during therapy and during assessments
  • use of medications that are know to modify tDCS effectiveness including those with anticholinergic, GABAergic, or glutamatergic properties, or sodium channel blockers
  • clinical judgment of investigative team

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

HealthStreet

Gainesville, Florida, 32608, United States

Location

UF Institute on Aging

Gainesville, Florida, 32611, United States

Location

University of Florida

Gainesville, Florida, 32611, United States

Location

Related Publications (1)

  • Chatterjee SA, Seidler RD, Skinner JW, Lysne PE, Sumonthee C, Wu SS, Cohen RA, Rose DK, Woods AJ, Clark DJ. Effects of Prefrontal Transcranial Direct Current Stimulation on Retention of Performance Gains on an Obstacle Negotiation Task in Older Adults. Neuromodulation. 2023 Jun;26(4):829-839. doi: 10.1016/j.neurom.2022.02.231. Epub 2022 Apr 8.

MeSH Terms

Conditions

Mobility LimitationCognitive Dysfunction

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsCognition DisordersNeurocognitive DisordersMental Disorders

Results Point of Contact

Title
Dr. David Clark
Organization
University of Florida

Study Officials

  • David Clark, ScD

    University of Florida

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
To control for intensity, participants will maintain a rating of perceived exertion of 4 (moderate to strong) on the Borg Category/Ratio Scale during walking. Exertion will be adjusted by modifying walking speed and/or by modifying the rest time between walking bouts.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will take part in a 6-week, 18-session neurorehabilitation led by qualified and trained study personnel. Participants will be randomized to one of three groups: 1) standard walking neurorehabilitation with sham tDCS ('standard/sham' group), 2) complex walking neurorehabilitation with sham tDCS ('complex/sham' group), or 3) complex walking neurorehabilitation with active anodal tDCS ('complex/active' group). Training logs will be maintained to gauge the content and intensity of training.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 7, 2017

First Posted

April 20, 2017

Study Start

June 1, 2017

Primary Completion

May 31, 2020

Study Completion

March 6, 2021

Last Updated

June 14, 2024

Results First Posted

June 14, 2024

Record last verified: 2024-06

Locations